recombinant human erythropoietin / Max Planck Institute, Pfizer 
Welcome,         Profile    Billing    Logout  
 5 Diseases   1 Trial   1 Trial   184 News 
  • ||||||||||  recombinant human erythropoietin / Max Planck Institute, Pfizer
    Preclinical, Journal:  Erythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus. (Pubmed Central) -  Oct 4, 2024   
    Metabolism and inhibitory potential of interneuron subgroups are compromised, leading to greater excitability of pyramidal neurons. To conclude, improvement by rhEPO of neuropsychiatric phenotypes may partly owe to restrictive control over interneurons, facilitating re-connectivity and synapse development.
  • ||||||||||  recombinant human erythropoietin / Max Planck Institute, Pfizer
    Forebrain specific loss of erythropoietin provokes a compensatory upregulation of different EPO receptors (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_8503;    
    Using our single-nuclei-RNA-seq dataset, we identify forebrain expression of Emx mainly in excitatory neurons with no alterations upon EPO. Collectively, these data explain the lack of behavioral and cognitive consequences on forebrain-wide elimination of EPO.
  • ||||||||||  recombinant human erythropoietin / Max Planck Institute, Pfizer
    Review, Journal:  Neuroprotective Effects of Moderate Hypoxia: A Systematic Review. (Pubmed Central) -  Dec 23, 2023   
    We identified 58 eligible studies (k = 8 human studies with N = 274 individuals; k = 48 animal studies) reporting the effects of hypoxia on cognition, motor function, neuroimaging, neuronal/synaptic morphology, inflammation, oxidative stress, erythropoietin, neurotrophins, and Alzheimer's disease markers...Low-dose intermittent or continuous hypoxia repeated for 30-240 min sessions, preferably in combination with motor-cognitive training, produced beneficial effects, and high-dose hypoxia with longer (?6 h) durations and chronic exposure produced more adverse effects. Larger and methodologically stronger translational studies are warranted.
  • ||||||||||  recombinant human erythropoietin / Max Planck Institute, Pfizer
    Pro-cognitive effects of intravenous erythropoietin in patientswith schizophrenia () -  Mar 10, 2023 - Abstract #SIRS2023SIR_260;    
    Nonetheless, EPO constitutes a promisingapproach to mitigate cognitive deficits in several patient groups allowing to improve functionaloutcome. Hence, further efforts to establish optimal administration protocols and to promote awidespread use should be supported.KeywordKeywordsCognitive Decline in SchizophreniaPharmacological Treatmentneurodevelopmental disorderspsychosis, cognition, negative symptoms, neurobiologyPoster Award YesPoster Award Eligibility - Young Investigator YesPoster Award Eligibility - SIRS Membership NoPlease list all co-authors for this poster submission.* Presenting AuthorFirst Name Last Name AffiliationMishal * Qubad * Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe University2Karlotta Jacobs Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityCatherine Barnes-Scheufler Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityMareike Aichholzer Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannah Wendy Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannelore Ehrenreich Clinical Neuroscience, Max PlanckInstitute of Experimental Medicine,G
  • ||||||||||  recombinant human erythropoietin / Max Planck Institute, Pfizer
    Journal:  For decades against the mainstream - From erythropoietin and hypoxia as novel treatment strategies to deep phenotyping in neuropsychiatric disorders. (Pubmed Central) -  Nov 18, 2022   
    Hence, further efforts to establish optimal administration protocols and to promote awidespread use should be supported.KeywordKeywordsCognitive Decline in SchizophreniaPharmacological Treatmentneurodevelopmental disorderspsychosis, cognition, negative symptoms, neurobiologyPoster Award YesPoster Award Eligibility - Young Investigator YesPoster Award Eligibility - SIRS Membership NoPlease list all co-authors for this poster submission.* Presenting AuthorFirst Name Last Name AffiliationMishal * Qubad * Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe University2Karlotta Jacobs Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityCatherine Barnes-Scheufler Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityMareike Aichholzer Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannah Wendy Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannelore Ehrenreich Clinical Neuroscience, Max PlanckInstitute of Experimental Medicine,G No abstract available
  • ||||||||||  recombinant human erythropoietin / Max Planck Institute, Pfizer
    Review, Journal:  Introducing the brain erythropoietin circle to explain adaptive brain hardware upgrade and improved performance. (Pubmed Central) -  May 31, 2022   
    Here we delineate the brain EPO circle as working model explaining adaptive 'brain hardware upgrade' and improved performance. In this fundamental regulatory circle, neuronal networks, challenged by motor-cognitive tasks, drift into transient 'functional hypoxia', thereby triggering neuronal EPO/EPOR expression.
  • ||||||||||  recombinant human erythropoietin / Max Planck Institute, Pfizer
    Clinical, Journal:  Brain erythropoietin fine-tunes a counterbalance between neurodifferentiation and microglia in the adult hippocampus. (Pubmed Central) -  Feb 12, 2022   
    Surprisingly, EPO affects microglia in phases, initially by inducing apoptosis, later by reducing proliferation, and overall dampens microglia activity and metabolism, as verified by selective genetic targeting of either the microglial or pyramidal neuronal EPO receptor. We suggest that during accelerating neuronal differentiation, EPO acts as regulator of the CSF1R-dependent microglia.
  • ||||||||||  recombinant human erythropoietin / Trillium Therap, Max Planck Institute
    Journal:  CaMKIIα Expressing Neurons to Report Activity-Related Endogenous Hypoxia upon Motor-Cognitive Challenge. (Pubmed Central) -  May 13, 2021   
    We previously introduced the brain erythropoietin (EPO) circle as a model to explain the adaptive 'brain hardware upgrade' and enhanced performance...To conclude, task-associated activity triggers neuronal functional hypoxia as a local and brain-wide reaction mediating adaptive neuroplasticity. Hypoxia-induced genes such as EPO drive neuronal differentiation, brain maturation, and improved performance.